Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tissue Repair Cells

Cell therapy · developed by Vericel

Phase 1/2 Most advanced trial (none active)
VCEL Developer
1 Registered trials

What is Tissue Repair Cells?

Tissue Repair Cells (ixmyelocel-t) are an autologous bone marrow tissue graft, processed from the patient's own aspirated bone marrow and absorbed onto a gelfoam carrier. They are studied for alveolar bone loss, with the cells placed in the tooth extraction socket.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Musculoskeletal
Developer
Vericel Corporation (VCEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00755911 Phase 1/2 Alveolar Bone Loss Completed VCEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alveolar Bone Loss

More from Vericel

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.

Follow VCEL, the company behind Tissue Repair Cells

See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VCEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.